 SAN DIEGO--BUSINESS WIRE--- GOSS--Gossamer Bio, Inc. Nasdaq: GOSS, a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced that it will report its fourth quarter and full-year 2020 financial results on Thursday, February 25, 2021. In connection with the earnings release, Gossamers management team will host a live conference call and webcast at 8:30 a.m. E 